Drug Trial Radar · NCT03568318
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,533
Actual
Start
Aug 9, 2018
Primary completion
Feb 16, 2021
Study completion Oct 23, 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Conditions
- Atopic Dermatitis
Interventions
PlaceboDrug
Tablets taken orally once a day
UpadacitinibDrug
Tablets taken orally once a day
Topical corticosteroids (TCS)Drug
Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity. Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16Time frame: Baseline and Week 16
- Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16Time frame: Baseline and Week 16
Locations
193 sites in 24 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Derm Ctr /ID# 200548
Birmingham, Alabama
Clinical Research Center AL /ID# 201865
Birmingham, Alabama
ACCEL Research Sites /ID# 213364
Birmingham, Alabama
Advanced Dermatology and Skin Care Centre /ID# 213550
Mobile, Alabama
Alliance Dermatology and MOHs Center, PC /ID#200540
Phoenix, Arizona
Arizona Research Center, Inc. /ID# 200546
Phoenix, Arizona
Clear Dermatology & Aesthetics Center /ID# 201257
Scottsdale, Arizona
University of Arizona /ID# 201059
Tucson, Arizona
Bakersfield Derma & Skin Cance /ID# 200892
Bakersfield, California
Mosaic Dermatology /ID# 200553
Beverly Hills, California
University of California Irvine /ID# 200902
Irvine, California
Therapeutics Clinical Research /ID# 200593
San Diego, California
Stanford University /ID# 200597
Stanford, California
Duplicate_University of Colorado Anchutz Medical Campus /ID# 202822
Aurora, Colorado
Colorado Center for Dermatology, PLLC /ID# 203626
Centennial, Colorado
Duplicate_Western States Clinical Research, Inc. /ID# 201702
Wheat Ridge, Colorado
Dermatology Physicians of Connecticut /ID# 201004
Shelton, Connecticut
Clearlyderm Dermatology /ID# 207709
Boca Raton, Florida
Skin Care Research, LLC /ID# 200812
Boca Raton, Florida
Clinical Research of West Florida, Inc /ID# 203643
Clearwater, Florida
Florida Academic Centers Research and Education /ID# 200544
Coral Gables, Florida
Tory P Sullivan, MD PA /ID# 201174
North Miami Beach, Florida
Park Avenue Dermatology, PA /ID# 201012
Orange Park, Florida
Precision Clinical Research /ID# 208734
Sunrise, Florida
Advanced Clinical Research at Treasure Valley Dermatology & Skin Cancer Center /ID# 203628
Boise, Idaho
Northwestern University Feinberg School of Medicine /ID# 201646
Chicago, Illinois
Northshore University Health System Dermatology Clinical Trials Unit /ID# 200556
Skokie, Illinois
DuPage Medical Group /ID# 202065
Wheaton, Illinois
Deaconess Clinic Downtown /ID# 201001
Evansville, Indiana
Indiana University /ID# 200515
Indianapolis, Indiana
Epiphany Dermatology of Kansas LLC /ID# 203026
Overland Park, Kansas
ORA, Inc. /ID# 202824
Andover, Massachusetts
Tufts Medical Center /ID# 200570
Boston, Massachusetts
Beth Israel Deaconess Medical Center /ID# 200545
Boston, Massachusetts
Clin Res Inst of Michigan, LLC /ID# 208020
Chesterfield, Michigan
Michigan Center for Research Company /ID# 200560
Clarkston, Michigan
MediSearch Clinical Trials /ID# 201006
Saint Joseph, Missouri
Skin Specialists, PC /ID# 200573
Omaha, Nebraska
Dartmouth-Hitchcock Medical Center /ID# 200918
Lebanon, New Hampshire
Psoriasis Treatment Center of Central New Jersey /ID# 200714
East Windsor, New Jersey
Showing 40 of 193 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.